Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Ares Commercial Real Estate Corp (NYSE: ACRE) shares declined1.63 percent to close at $15.67 a share Tuesday. The stock traded between $14.70 and $18.65 on volume of 802,613 shares traded. The company announced plans for a public offering of 18 million shares of its common stock. Shares of Ares Commercial Real Estate have fallen approximately 4.6 percent year-to-date.
Get more information on Ares Commercial Real Estate and free access to the in-depth equity report at:
www.FiveStarEquities.com/ACRE
FactSet Research Systems Inc. (NYSE: FDS) shares declined4.47 percent to close at $99.12 a share Tuesday. The stock traded between $96.87 and $101.93 on volume of 1.89 million shares traded. The company reported revenues of $214.6 million for the third quarter of fiscal 2013, an increase of 6 percent when compared to the year ago quarter. Shares of FactSet Research Systems have gained approximately 12.5 percent year-to-date.
Get more information on FactSet Research Systems and free access to the in-depth equity report at:
www.FiveStarEquities.com/FDS
Repros Therapeutics Inc. (NASDAQ: RPRX) shares spiked 7.03 percent to close at $19.19 a share Tuesday. The stock traded between $17.00 and $19.99 on volume of 717,496 shares traded. The company announced plans for a public offering of up to 3 million shares of its common stock. Shares of Repros Therapeutics have gained approximately 21.8 percent year-to-date.
Get more information on Repros Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/RPRX
Valeant Pharmaceuticals Intl Inc. (NYSE: VRX)(TSX: VRX) shares gained 1.23 percent to close at $85.86 a share Tuesday. The stock traded between $83.86 and $88.67 on volume of 2.44 million shares traded. The company announced plans to raise $1.75 billion though a public offering of its common stock to help fund its acquisition of Bausch + Lomb Holdings Inc. Shares of Valeant Pharmaceuticalshave gained approximately 43.7 percent year-to-date.
Get more information on Valeant Pharmaceuticals and free access to the in-depth equity report at:
www.FiveStarEquities.com/VRX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com